RDHL.TA - RedHill Biopharma Ltd.

Tel Aviv - Tel Aviv Delayed Price. Currency in ILS

RedHill Biopharma Ltd.

21 Ha'arba'a Street
Tel Aviv 6473921
Israel
972 3 541 3131
http://www.redhillbio.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees75

Key Executives

NameTitlePayExercisedYear Born
Mr. Dror Ben-AsherCo-Founder, Chairman & CEO442.95kN/A1966
Mr. Micha Ben-ChorinChief Financial Officer343.66kN/A1969
Mr. Gilead RadayChief Operating Officer333.07kN/A1975
Mr. Adi FrishSr. VP of Bus. Devel. & Licensing348.52kN/A1970
Mr. Guy GoldbergChief Bus. Officer346.14kN/A1976
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in ILS.

Description

RedHill Biopharma Ltd., a specialty biopharmaceutical company, focuses on the development and commercialization of clinical late-stage drugs for the treatment of gastrointestinal diseases in the United States. The company commercializes and promotes various gastrointestinal products, including Donnatal, a prescription oral adjunctive drug used in the treatment of irritable bowel syndrome (IBS) and acute enterocolitis; EnteraGam, a medical food for the dietary management of chronic diarrhea and loose stools; and Mytesi, an anti-diarrheal drug for the symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on anti-retroviral therapy. Its principal clinical late-stage development programs include Talicia for the treatment and eradication of Helicobacter pylori infection for which an NDA submitted and accepted for priority review; RHB-104 with positive results from a first Phase 3 study for crohn's disease; RHB-204, a planned pivotal Phase 3 study drug for pulmonary nontuberculous mycobacteria infections; BEKINDA with positive results from a first Phase 3 study for acute gastroenteritis and gastritis, as well as from a Phase 2 study for IBS with diarrhea; YELIVA, a selective inhibitor for multiple oncology, inflammatory, and gastrointestinal indications with an ongoing Phase 2a studies for cholangiocarcinoma; RHB-106, an encapsulated bowel preparation; and RHB-107, a Phase 2-stage serine protease inhibitor for cancer and inflammatory gastrointestinal diseases. The company was founded in 2009 and is headquartered in Tel Aviv, Israel.

Corporate Governance

RedHill Biopharma Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.